Patient Rating:

4.7 out of 5

100 Patient Ratings
51 Patient Comments

Howard Colman, M.D., Ph.D.

Patient Rating:

4.7 out of 5

100 Patient Ratings
51 Patient Comments

Clinical Details

Phone Number Clinical Office Address
(801) 585-0262
Huntsman Cancer Institute
Clinic 2E, Neuro
2000 Circle of Hope
Salt Lake City, UT 84112
Map
Veterans Administration Medical Center
500 S Foothill Blvd
Salt Lake City, UT 84149

Bio

Howard Colman, MD, PhD, has multiple clinical interests including the treatment of primary and metastatic brain tumors, and the diagnosis and management of neurologic complications of cancer. His clinical research is focused on the development and testing of new therapies for brain tumors. His laboratory interests include the identification of molecular markers of prognosis and treatment response in brain tumors and the role of tumors stem cells in the development and treatment resistance of brain tumors. He is an associate professor in the Department of Neurosurgery, a member of the multidisciplinary Brain Tumor Research Team, and is Director of Medical Neuro-Oncology at Huntsman Cancer Institute.

Board Certification and Academic Information

Academic Departments Neurosurgery - Professor
Internal Medicine - Adjunct Associate Professor
Neurology - Adjunct Associate Professor
Academic Divisions Adult Neurosurgery
Oncology
Board Certification American Board of Psychiatry & Neurology
United Council for Neurologic Subspecialties (Neuro-oncology)
Cancer Center Programs Experimental Therapeutics

Patient Ratings

The Patient Rating score is an average of all responses to care provider related questions on our nationally-recognized Press Ganey Patient Satisfaction Survey.

Responses are measured on a scale of 1 to 5 with 5 being the best score.

Likelihood of recommending care provider
4.7
My confidence in care provider
4.7
Time care provider spent with me
4.6
Care provider spoke using clear language
4.7
Care provider's effort to include me in decisions
4.6
Care provider's concern for questions & worries
4.6
Care provider's explanation of condition/problem
4.7
Wait time at clinic
3.7
Care provider's friendliness and courtesy
4.7

Patient Comments

Patient comments are gathered from our Press Ganey Patient Satisfaction Survey and displayed in their entirety. Patients are de-identified for confidentiality and patient privacy.

April 13, 2016

very good

April 10, 2016

no complaints. I have complete confidence in this team

February 11, 2016

I am one of those that typically gives strong critical feedback, especially negative in nature when it is appropriate. I don't have any related to this visit. The Doctor was courteous, on time, and straightforward.

January 11, 2016

I am the second person in my family to meet with this doctor. He took great care to be sure we were comfortable.

January 07, 2016

The Medical Doctor was very helpful and thoughtful. The Technician during the MRI "Rey" was wonderful. He made the MRI experience very pleasant!

November 08, 2015

Your care providers have been great

October 10, 2015

Dr. Coleman is very good at explaining everything

September 23, 2015

I think Dr. Colman is one of the best Nero oncologist in the country. I fly once a year to see him. The trip cost me about $500.00 round trip. I could go to a doctor that is closer but I trust him. He doesn't sugar coat anything and I like that.

September 21, 2015

A great team and they include the patient (and family) in the discussions.

September 09, 2015

Very pleased with our experience and care.

August 24, 2015

great care providers

July 12, 2015

Very happy with Dr. Colman.

July 05, 2015

So far life is good!

July 02, 2015

Sean and Dr. Coleman are both professional and friendly, spend all the time we need and we like them and the care they give.

June 12, 2015

i love love love Kylee, Shawn and Dr. Colman. they make a great team and ALWAYS go the extra mile for anything i need. They are all SUPER compassionate and caring. im glad i FINALLY found a great healthcare team for myself.

May 19, 2015

good

May 11, 2015

The opportunity to work with such an amazing team of professionals almost makes it worth it to have cancer.

April 13, 2015

Dr. Colman is very friendly and always answers my questions and concerns. I feel very blessed to have him as my Dr.

February 16, 2015

My team is great! I am so happy I finally got referred here.

January 28, 2015

Very good Experience

January 12, 2015

Dr. Colman has always fully answered any concerns or questions we might have. We have full trust in his care.

January 10, 2015

Dr. Colman and his staff are awesome. I apologize but I don't know the doctor's name who saw me before Dr. Colman but he was great. He answered my questions and I could tell he was interested in how I was doing and what had gone on since the last time I was there. Dr. Colman was fantastic. I was very glad to hear that he is also over at the VA hospital. He showed me my tumor on the scan and answered all my questions. I trust him with my care.

January 10, 2015

We had a very good experience with Dr. Colman, Sean PA, and nurse Kylee. All 3 were professional and caring. I am so happy I finally found a great team to take care of me. Healthcare these days seems lousy at best, but this team is PHENOMINAL!!!!!!! CANT SAY ENOUGH GOOD ABOUT THEM. THANK YOU THANK YOU THANK YOU!!!!!!!

January 03, 2015

don't get me wrong my medical team is great and wouldn't trade them and I know they're busy but I'm busy too !!!!!

November 01, 2014

Not impressed. When you have cancer their should always be some hope

October 19, 2014

Dr and Assistant are exceptional. We feel very comfortable with them and are able to express our concerns and ask questions.

October 04, 2014

We feel very confidante with Dr Colman

October 03, 2014

Dr. Colman is a genius. He knows absolutely everything there is to know about brain tumors. He was great at educating us about the tumor and the medicine that would help it. I was slightly disappointed by our method of communication. He seemed to feel rushed and wanted to leave as soon as possible. He answered all of our questions, but a patient with a brain tumor needs time to process information.

April 07, 2014

I have been to the clinic for 20 years but had a new doctor at this visit. Dr. Colman was very thorough, informative and patient.

April 06, 2014

Dr Colman is great, his son played lacrosse with my son a few years ago, so he is willing to chat with me personally for a few minutes as well as being very professional in his medical care for me.

March 30, 2014

I was very impressed with the quality of care at Huntsman. We have been to UCLA medical several times and we just moved to Utah and this was a vast improvement over the care we received at UCLA.

March 15, 2014

just like the nursing staff, the PA/MD seemed to be in a hurry. However they seemed to be doing their best to answer all of my questions and not rush the appt

February 03, 2014

I was very impressed that I transferred my care to Hunstman from IMC.

October 30, 2013

The nurse, PA, and doctor were all fantastic and thorough and provided all the information I needed in a way that was easy to understand.

July 06, 2013

love dr Colman. and his staff

May 31, 2013

Very Positive Experience.

May 27, 2013

I have the highest confidence in Dr Colman. He is an excellent physician.

April 22, 2013

Dr Colman is excellent. I respect him and have a significant amount of confidence in his professional ability.

March 28, 2013

I have a lot of confidence in my medical care team.

February 18, 2013

Over the top. I left feeling hopeful and extremely confident with dr Coleman and the entire team

January 22, 2013

I was very happy with the care I was given. I was especially surprised with the degree of time the doctor and pa gave me. Their concern for me was genuine and they made me feel relaxed and better able to understand what they were saying.

November 19, 2012

Very clearly outlined the next few steps in my treatment

November 19, 2012

All clinic staff (doctor, pa, and np) listened carefully to my questions, gave thorough answers and explanations, and made sure I understood next steps.

November 05, 2012

I have recommended to many of my co-workers and family out of state about how awesome our experience was.

August 20, 2012

Dr. Colman is awesome that is all that needs to be said.

July 03, 2012

Between all the staff I was provided with almost 1.5 hours of care during my visit. This was outstanding. Dr Colman was very detail oriented and never seemed rushed - I really appreciated this. The PA seemed very knowledgeable, but very rushed.

June 13, 2012

Dr. Howard Colman, has been very understanding, and communicates clearly, in a manner we can fully understand.

April 27, 2012

Dr. Colman is always well informed on Sherry's latest MRI's and treatments. He gives us substantial input.

March 14, 2012

Include me in the process of making a diagnosis and prescribing the right medication. They are not just doctors that tell you what to do because they said so. They are very involved in what's going on in the patient's mind.

February 22, 2012

They addressed every concern.

January 11, 2012

I am very grateful for the care that I have recieved from Dr. Howard Colman. I have the upmost confidence in them and the way they have treated my condition.

Academic Profile

Research Interests

  • Clinical Trials
  • Identification of Molecular Markers of Prognosis and Treatment Response in Brain Tumors
  • Role of Tumors Stem Cells in the Development and Treatment Resistance of Brain Tumors
  • Brain Tumors
  • Development and Testing of New Therapies for Brain Tumors

Board Certification and Academic Information

Academic Departments Neurosurgery - Professor
Internal Medicine - Adjunct Associate Professor
Neurology - Adjunct Associate Professor
Academic Divisions Adult Neurosurgery
Oncology
Board Certification American Board of Psychiatry & Neurology
United Council for Neurologic Subspecialties (Neuro-oncology)
Cancer Center Programs Experimental Therapeutics

Academic Office Locations

Academic Office Phone Number Academic Office Address
(801) 587-4024 Huntsman Cancer Institute
2000 Circle of Hope
Salt Lake City, UT 84112

Academic Bio

Howard Colman, MD, PhD, has multiple clinical interests including the treatment of primary and metastatic brain tumors, and the diagnosis and management of neurologic complications of cancer. His clinical research is focused on the development and testing of new therapies for brain tumors. His laboratory interests include the identification of molecular markers of prognosis and treatment response in brain tumors and the role of tumors stem cells in the development and treatment resistance of brain tumors. He is an associate professor in the Department of Neurosurgery, a member of the multidisciplinary Brain Tumor Research Team, and is Director of Medical Neuro-Oncology at Huntsman Cancer Institute (HCI) at the University of Utah. He is also an HCI investigator and a member of the Experimental Therapeutics program.

Education

Education History

Type School Degree
Fellowship University of Texas M.D. Anderson Cancer Center
Neuro-Oncology
Fellow
Chief Resident Washington University School of Medicine
Neurology
Chief Resident
Residency Barnes-Jewish Hospital, Washington University School of Medicine
Neurology
Resident
Internship Barnes-Jewish Hospital, Washington University School of Medicine
Medicine
Intern
Professional Medical Washington University School of Medicine
Medicine
M.D.
Doctoral Training Washington University School of Medicine
Neuroscience
Ph.D.
Undergraduate Brown University
Neural Sciences
Sc.B.

Publications

Selected Provider Publications

Journal Article

  1. Ramaswamy V, Hielscher T, Mack SC, Lassaletta A, Lin T, Pajtler KW, Jones DT, Luu B, Cavalli FM, Aldape K, Remke M, Mynarek M, Rutkowski S, Gururangan S, McLendon RE, Lipp ES, Dunham C, Hukin J, Eisenstat DD, Fulton D, van Landeghem FK, Santi M, van Veelen MC, Van Meir EG, Osuka S, Fan X, Muraszko KM, Tirapelli DP, Oba-Shinjo SM, Marie SK, Carlotti CG, Lee JY, Nageswara Rao AA, Giannini C, Faria CC, Nunes S, Mora J, Hamilton RL, Hauser P, Jabado N, Petrecca K, Jung S, Massimi L, Zollo M, Cinalli G, Bognr L, Klekner A, Hortobgyi T, Leary S, Ermoian RP, Olson JM, Leonard JR, Gardner C, Grajkowska WA, Chambless LB, Cain J, Eberhart CG, Ahsan S, Massimino M, Giangaspero F, Buttarelli FR, Packer RJ, Emery L, Yong WH, Soto H, Liau LM, Everson R, Grossbach A, Shalaby T, Grotzer M, Karajannis MA, Zagzag D, Wheeler H, von Hoff K, Alonso MM, Tuon T, Schller U, Zitterbart K, Sterba J, Chan JA, Guzman M, Elbabaa SK, Colman H, Dhall G, Fisher PG, Fouladi M, Gajjar A, Goldman S, Hwang E, Kool M, Ladha H, Vera-Bolanos E, Wani K, Lieberman F, Mikkelsen T, Omuro AM, Pollack IF, Prados M, Robins HI, Soffietti R, Wu J, Metellus P, Tabori U, Bartels U, Bouffet E, Hawkins CE, Rutka JT, Dirks P, Pfister SM, Merchant TE, Gilbert MR, Armstrong TS, Korshunov A, Ellison DW, Taylor MD (2016). Therapeutic Impact of Cytoreductive Surgery and Irradiation of Posterior Fossa Ependymoma in the Molecular Era: A Retrospective Multicohort Analysis [Epub ahead of print]. J Clin Oncol, 34(21), 2468-2477.
  2. Ceccarelli M, et al TCGA Research Network, Colman H (2016). Molecular Profiling Reveals Biologically Discrete Subsets and Pathways of Progression in Diffuse Glioma. Cell, 146(3), 550-563.
  3. Butowski N, Colman H, De Groot JF, Omuro AM, Nayak L, Wen PY, Cloughesy TF, Marimuthu A, Haidar S, Perry A, Huse J, Phillips J, West BL, Nolop KB, Hsu HH, Ligon KL, Molinaro AM, Prados M (2016). Orally administered colony stimulating factor 1 receptor inhibitor PLX3397 in recurrent glioblastoma: an Ivy Foundation Early Phase Clinical Trials Consortium phase II study. Neuro Oncol, 18(4), 557-64.
  4. Sivakumar W, Oh N, Cutler A, Colman H, Couldwell WT (2015). Cranial and spinal leptomeningeal dissemination in esthesioneuroblastoma: Two reports of distant central nervous system metastasis and rationale for treatment. Surg Neurol Int, 6(Suppl 25), S628-32.
  5. Sathyan P, Zinn PO, Marisetty AL, Liu B, Kamal MM, Singh SK, Bady P, Lu L, Wani KM, Veo BL, Gumin J, Kassem DH, Robinson F, Weng C, Baladandayuthapani V, Suki D, Colman H, Bhat KP, Sulman EP, Aldape K, Colen RR, Verhaak RG, Lu Z, Fuller GN, Huang S, Lang FF, Sawaya R, Hegi MAUID- ORCID httporcidorg0000-0003-0855-6495, Majumder S (2015). Mir-21-Sox2 Axis Delineates Glioblastoma Subtypes with Prognostic Impact. J Neurosci, 35(45), 15097-112.
  6. Yuan S, Lu Y, Yang J, Chen G, Kim S, Feng L, Ogasawara M, Hammoudi N, Lu W, Zhang H, Liu J, Colman H, Lee JS, Li XN, Xu RH, Huang P, Wang F (2015). Metabolic activation of mitochondria in glioma stem cells promotes cancer development through a reactive oxygen species-mediated mechanism. Stem Cell Res Ther, 6(1), 198.
  7. Balasubramaniyan V, Vaillant B, Wang S, Gumin J, Butalid ME, Sai K, Mukheef F, Kim SH, Boddeke HW, Lang F, Aldape K, Sulman EP, Bhat KP, Colman H (2015). Aberrant mesenchymal differentiation of glioma stem-like cells: implications for therapeutic targeting. Oncotarget, 6(31), 31007-17.
  8. Hossain A, Gumin J, Gao F, Figueroa J, Shinojima N, Takezaki T, Priebe W, Villarreal D, Kang SG, Joyce C, Sulman E, Wang Q, Marini FC, Andreeff M, Colman H, Lang FF (2015). Mesenchymal Stem Cells Isolated From Human Gliomas Increase Proliferation and Maintain Stemness of Glioma Stem Cells Through the IL-6/gp130/STAT3 Pathway. Stem Cells, 33(8), 2400-15.
  9. Cohen A, Sato M, Aldape K, Mason CC, Alfaro-Munoz K, Heathcock L, South ST, Abegglen LM, Schiffman JD, Colman H (2015). DNA copy number analysis of Grade II-III and Grade IV gliomas reveals differences in molecular ontogeny including chromothripsis associated with IDH mutation status. Acta Neuropathol Commun, 3, 34.
  10. Vera-Bolanos E, Aldape K, Yuan Y, Wu J, Wani K, Necesito-Reyes MJ, Colman H, Dhall G, Lieberman FS, Metellus P, Mikkelsen T, Omuro A, Partap S, Prados M, Robins HI, Soffietti R, Wu J, Gilbert MR, Armstrong TS (2015). Clinical course and progression-free survival of adult intracranial and spinal ependymoma patients. Neuro-Oncol, 17(3), 440-447.
  11. The Cancer Genome Atlas Network (2015). Comprehensive and Integrative Genomic Characterization of Diffuse Lower Grade Gliomas DOI: 10.1056/NEJMoa1402121 *Includes Colman, H. N Engl J Med, 372(26), 2481-2498.
  12. Choi H, Gillespie DL, Berg S, Rice C, Couldwell S, Gu J, Colman H, Jensen RL, Huang LE (2015). Intermittent induction of HIF-1alpha produces lasting effects on malignant progression independent of its continued expression. PLoS One, 10(4), e0125125.
  13. Chen R, Ravindra VM, Cohen AL, Jensen RL, Salzman KL, Prescot AP, Colman H (2015). Molecular features assisting in diagnosis, surgery, and treatment decision making in low-grade gliomas. Neurosurg Focus, 38(3), E2.
  14. Karsy M, Neil JA, Guan J, Mahan MA, Colman H, Jensen RL (2015). A practical review of prognostic correlations of molecular biomarkers in glioblastoma. Neurosurg Focus, 38(3), E4.
  15. Penas-Prado M, Hess KR, Fisch MJ, Lagrone LW, Groves MD, Levin VA, De Groot JF, Puduvalli VK, Colman H, Volas-Redd G, Giglio P, Conrad CA, Salacz ME, Floyd JD, Loghin ME, Hsu SH, Gonzalez J, Chang EL, Woo SY, Mahajan A, Aldape KD, Yung WK, Gilbert MR (2015). Randomized phase II adjuvant factorial study of dose-dense temozolomide alone and in combination with isotretinoin, celecoxib, and/or thalidomide for glioblastoma. Neuro Oncol, 17(2), 266-73.
  16. Cohen AL, Colman H (2015). Glioma biology and molecular markers. Cancer Treat Res, 163, 15-30.
  17. Saito N, Fu J, Zheng S, Yao J, Wang S, Liu DD, Yuan Y, Sulman EP, Lang FF, Colman H, Verhaak RG, Yung WK, Koul D (2014). A high Notch pathway activation predicts response to gamma secretase inhibitors in proneural subtype of glioma tumor-initiating cells. Stem Cells, 32(1), 301-12.
  18. Gilbert MR, Dignam JJ, Armstrong TS, Wefel JS, Blumenthal DT, Vogelbaum MA, Colman H, Chakravarti A, Pugh S, Won M, Jeraj R, Brown PD, Jaeckle KA, Schiff D, Stieber VW, Brachman DG, Werner-Wasik M, Tremont-Lukats IW, Sulman EP, Aldape KD, Curran WJ Jr, Mehta MP (2014). A randomized trial of bevacizumab for newly diagnosed glioblastoma. N Engl J Med, 370(8), 699-708.

Review

  1. Chen R, Cohen AL, Colman H (2016). Targeted Therapeutics in Patients With High-Grade Gliomas: Past, Present, and Future. [Review]. Curr Treat Options Oncol, 17(8), 42.
  2. Karsy M, Guan J, Cohen A, Colman H, Jensen RL (2016). Medical Management of Meningiomas: Current Status, Failed Treatments, and Promising Horizons. [Review]. Neurosurg Clin N Am, 27(2), 249-60.
  3. Karsy M, Guan J, Jensen R, Huang LE, Colman H (2016). The Impact of Hypoxia and Mesenchymal Transition on Glioblastoma Pathogenesis and Cancer Stem Cells Regulation. [Review]. World Neurosurg, 88, 222-36.
  4. Prados MD, Byron SA, Tran NL, Phillips JJ, Molinaro AM, Ligon KL, Wen PY, Kuhn JG, Mellinghoff IK, de Groot JF, Colman H, Cloughesy TF, Chang SM, Ryken TC, Tembe WD, Kiefer JA, Berens ME, Craig DW, Carpten JD, Trent JM (2015). Toward precision medicine in glioblastoma: the promise and the challenges. [Review]. Neuro-Oncology, 17(8), 1051-1063.

Clinical Trials

Video & News

Video